Merck Serono Increases Oncology Medical Representatives To Expand Japanese Market
This article was originally published in PharmAsia News
Executive Summary
With the recent market launch of colon cancer drug Erbitux (cetuximab), German drug maker Merck Serono plans to add 20 to 40 oncology medical representatives in three years in Japan. Merck Serono currently has 60 oncology MRs in Japan. Merck Serono's president estimated that as colon cancer will likely top cancer cases in Japan by 2020, Erbitux could become a blockbuster drug. (Click here for more - Japanese language
You may also be interested in...
YM Bioscience's EGFR-targeting Drug Goes Into Phase III Trials In Singapore
SHANGHAI - National Cancer Centre of Singapore will sponsor YM Bioscience's nimotuzumab for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck, the company recently announced
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.